The Food and Drug Administration has approved a topical wipe that can help curtail excessive underarm sweating, the company behind the product announced Friday.
Qbrexza is a cloth that can be applied to the skin daily to reduce perspiration by blocking sweat gland activation, according to an announcement from manufacturer Dermira. The product offers a subtle solution to the millions of people who suffer from primary focal axillary hyperhidrosis, or excessive underarm sweating, which is currently often treated with Botox and other more invasive options.
In two clinical trials, Qbrexza was shown to reduce patients’ sweat production and severity, according to Dermira. Possible side effects include dryness of the skin, mouth, eyes, nose and throat; sore throat; headaches; blurred vision and dilated pupils; and constipation and trouble urinating.
The product is approved for patients nine and older, and is expected to hit pharmacies in October, according to the announcement. Dermira has not disclosed pricing information.
- Here's Where All The Strongest Hurricanes Have Hit the U.S. in the Past 50 Years
- 2022 Time100 NEXT: TIME’s List Of Emerging Leaders Who Are Shaping the Future
- Industrial Farming Causes Climate Change. The ‘Slow Food’ Movement Wants to Stop It
- Here Are the 12 New Books You Should Read in October
- Artist Oliver Jeffers Wants to Paint the World Out of a Corner
- A Vibrant North Korean Community in London Finds Its Days Are Numbered
- COVID-19 Vaccines Can Make Periods Longer, Study Says
- Column: What Happened When My Entire Family Came Out